FinTech
Starpharma: Receives $7.1m R&D tax incentive refund
Starpharma Receives $7.1m R&D tax incentive refundBiopharmaceutical company Starpharma (SPL) receives a $7.1 million research and development tax incentive refund
The tax offset...
FinTech
Starpharma: Registers VIRALEZE nasal spray in Indonesia
Starpharma Registers VIRALEZE nasal spray in IndonesiaStarpharma (SPL) registers its nasal spray product VIRALEZE in Indonesia after gaining marketing authorisation
The company says...
FinTech
Starpharma: Spends September quarter progressing DEP technology
Starpharma Spends September quarter progressing DEP technologyStarpharma (SPL) spent the September quarter progressing its DEP technology and signing a new research agreement
In...
FinTech
Starpharma: Expands research program with Genentech
Starpharma Expands research program with GenentechStarpharma (SPL) expands its research agreement with Genentech for its drug delivery technology, DEP
The initial agreement was...
FinTech
Starpharma: Receives $7.7m R&D tax refund
Starpharma Receives $7.7m R&D tax refundStarpharma (SPL) receives a $7.7 million research and development tax incentive refund
The refund falls under the Australian...
FinTech
Starpharma: Continues VIRALEZE success in December quarter
Starpharma Continues VIRALEZE success in December quarterStarpharma (SPL) releases its September quarterly report, with the period again highlighted by the continued success of...
FinTech
Starpharma: Advances progress for COVID-19 nasal spray
During the September quarter, Starpharma (SPL) achieved several milestones with its SPL7013 COVID-19 nasal spray
Additionally, the pharmaceutical company made progress with its...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read
